Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC
The triple therapy regimen comprising TAT-Bev-ICIs emerged as a promising therapeutic strategy for locally advanced hepatocellular carcinoma (HCC) as a neoadjuvant intervention.
Authors
- Dandan Hu (ORCID: https://orcid.org/0000-0001-7905-8536)
- Yizhen Fu (ORCID: https://orcid.org/0000-0003-1919-7176)
- Xiaoxian Sima
- Zhenyun Yang (ORCID: https://orcid.org/0000-0001-9526-7741)
- Hu Li (ORCID: https://orcid.org/0000-0002-7917-7807)
- Juncheng Wang (ORCID: https://orcid.org/0000-0003-0972-9511)
- Qianyu Wang (ORCID: https://orcid.org/0000-0001-7048-8847)
- Minshan Chen (ORCID: https://orcid.org/0000-0002-6116-5015)
- Zhongguo Zhou
- Yao‐Jun Zhang (ORCID: https://orcid.org/0000-0001-8357-5544)
Institutions
- Sun Yat-sen University (CN)
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-23
- DOI
- https://doi.org/10.3389/fimmu.2024.1469302
- Citations
- 4
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.48
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Guangzhou Municipal Science and Technology Project
- Basic and Applied Basic Research Foundation of Guangdong Province